Exelixis: Good Time To Buy [Seeking Alpha]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Seeking Alpha
Exelixis: Good Time To Buy Summary Double-digit sales growth. Positive cash flow from operations. Consensus buy ratings. Exelixis, Inc. ( EXEL After the market drops of last week, the stock is trading at a discount of about $1 to its 50-day and 200-day averages. ß EXEL appears to have resumed its pursuit of new markets for existing drugs, by conducting trials to prove efficacy for approved therapies on closely related diseases, after a decade of concentrating on marketing its approved products, which only recently (last three years) took the company to profitability. Its three-year return on sales is about 25.9% and return on invested capital for the period is about 20.4%. EXEL stock currently sells at about 9 times 2018 earnings of $2.21 per share. A recent article on Simply Wall Street ( Estimating The Fair Value Of Exelixis, Inc. (EXEL) Exelixis Expands Its Sales The questions for EXEL investors are (A) whether EXEL can continue its recent growth rate, and (B) whether it can produ
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024 [Seeking Alpha]Seeking Alpha
- 2 More Potential Biotech Buyout Targets [Seeking Alpha]Seeking Alpha
- Exelixis, Inc.'s (NASDAQ:EXEL) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? [Yahoo! Finance]Yahoo! Finance
- Exelixis, Inc. (NASDAQ: EXEL) was upgraded by analysts at TheStreet from a "c+" rating to a "b-" rating.MarketBeat
- Prostate Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 2/6/24 - Beat
EXEL
Sec Filings
- 3/25/24 - Form 4
- 3/21/24 - Form 144
- 2/27/24 - Form 4
- EXEL's page on the SEC website